To build near-term commercial opportunities, Agenus seeks to in-license immuno-oncology assets that complement and offer compelling combination therapy opportunities with our current portfolio, from preclinical to late stage development. We are also interested in platform technologies with the potential to enhance our capabilities to generate revenues from multiple product and combination product opportunities. For further information, please contact Business Development through our contact form below.
Agenus is interested in additional partnerships that leverage our portfolio of products and platform technologies including our checkpoint modulators, vaccine candidates, and QS-21 Stimulon® adjuvant. The targeted partnerships are designed to accelerate timelines of development as well as significantly enhance the market potential of our portfolio of products. We are also interested in deploying our antibody discovery platforms towards the development of novel therapeutic antibodies with applications beyond immuno-oncology with selected partners. For further information, please contact Business Development through our contact form below.
Agenus is committed to developing therapies for patients with cancer. Our goal is to provide access to our investigational therapies at the appropriate time and in the correct manner for patients. You can find information on access here: Agenus Compassionate Use Policy.